Cystic Fibrosis (CF) is a life-shortening, genetic disease in Europe afflicting about 30,000 individuals in the European Union (EU). Mutations in a single gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) cause CF and a spectr um of related disorders. Despite impressive advances in understanding the disease, patient life expectancy and quality of life remain limited because resources are scattered in Europe. Thus, CF remains a serious medical issue for Europe. CF highlights the complex challenges of genetic diseases in the post-genomic era, pioneering explanations for pathological mechanisms and rational approaches to therapy. Because CF causes severe lung disease, the main respiratory diseases affecting EU-populations mig ht ultimately benefit from advancements in CF research. Moreover, CF is a model monogenic disorder for molecular medicine, with its complex pathogenesis serving as a paradigm for the study of important multifactorial diseases. Building on the success of the FP5-funded CF Thematic Network (www.cfnetwork.be), a three-year Coordination Action, EuroCareCF (European Coordination Action for Research in Cystic Fibrosis) will unite CF research in Europe. EuroCareCF will translate research results into optimise d clinical management and therapy development to promote good standards of care for European CF patients.
Call for proposal
See other projects for this call
Funding SchemeCA - Coordination action